Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$14.15 USD
+0.33 (2.39%)
Updated Apr 26, 2024 04:00 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Urogen Pharma falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 138 | 101 | 90 | 103 | 148 |
Receivables | 15 | 13 | 12 | 7 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 4 | 5 | 2 | 0 |
Other Current Assets | 10 | 11 | 7 | 3 | 1 |
Total Current Assets | 169 | 129 | 114 | 116 | 149 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 1 |
Investments & Advances | 5 | 0 | 1 | 2 | 49 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 2 | 0 | 0 |
Total Assets | 178 | 136 | 120 | 122 | 202 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 12 | 12 | 10 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 8 | 7 | 10 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 3 | 2 | 2 |
Total Current Liabilities | 31 | 24 | 22 | 21 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 99 | 98 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 113 | 102 | 89 | 3 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 244 | 225 | 111 | 26 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 614 | 488 | 476 | 453 | 408 |
Retained Earnings | -679 | -577 | -467 | -357 | -228 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -65 | -89 | 8 | 96 | 180 |
Total Liabilities & Shareholder's Equity | 178 | 136 | 120 | 122 | 202 |
Total Common Equity | -65 | -89 | 8 | 96 | 180 |
Shares Outstanding | 23.40 | 22.70 | NA | 20.90 | 20.90 |
Book Value Per Share | -2.79 | -3.94 | 0.00 | 4.61 | 8.63 |
Fiscal Year End for Urogen Pharma falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 138 | 148 | 48 | 66 |
Receivables | NA | 15 | 13 | 16 | 12 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 6 | 5 | 5 | 5 |
Other Current Assets | NA | 10 | 16 | 13 | 12 |
Total Current Assets | NA | 169 | 182 | 81 | 96 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 5 | 7 | 8 | 10 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 3 | 3 |
Total Assets | NA | 178 | 194 | 95 | 113 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 17 | 14 | 16 | 17 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 11 | 8 | 7 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 4 | 4 | 4 | 3 |
Total Current Liabilities | NA | 31 | 26 | 27 | 25 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 99 | 99 | 98 | 98 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 110 | 108 | 105 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 244 | 236 | 234 | 230 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 614 | 611 | 493 | 491 |
Retained Earnings | NA | -679 | -653 | -631 | -607 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -65 | -42 | -138 | -117 |
Total Liabilities & Shareholder's Equity | NA | 178 | 194 | 95 | 113 |
Total Common Equity | 0 | -65 | -42 | -138 | -117 |
Shares Outstanding | 23.40 | 23.40 | 23.40 | 23.40 | 23.40 |
Book Value Per Share | 0.00 | -2.79 | -1.79 | -5.92 | -4.98 |